Avalo Therapeutics, Inc.
AVTX
59 insider filings · Latest: Sep 30, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | May 11 8:05 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 18,606 | $24.12 | $448.8K | 423(D) | View → |
| May 7, 2026 | May 7 8:20 PM | CHRISTOPHER SULLIVAN | Proposed Sale | 18,606 | $21.81 | $405.8K | — | View → |
| May 6, 2026 | May 7 8:18 PM | Paul VarkiChief Legal Officer | Sale | 75,063 | $20.17 | $1.5M | 3,634(D) | View → |
| May 6, 2026 | May 7 8:16 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 47,000 | $20.19 | $948.7K | 423(D) | View → |
| May 6, 2026 | May 7 8:16 PM | Mittie DoyleChief Medical Officer | Sale | 106,555 | $20.68 | $2.2M | 3,622(D) | View → |
| May 5, 2026 | May 7 8:16 PM | Mittie DoyleChief Medical Officer | Sale | 1,679 | $16.00 | $26.9K | 3,622(D) | View → |
| May 6, 2026 | May 7 8:15 PM | Mitchell ChanDirector | Sale | 3,167 | $22.88 | $72.5K | 3,166(D) | View → |
| May 6, 2026 | May 6 8:54 PM | MITTIE DOYLE | Proposed Sale | 54,508 | $16.26 | $886.3K | — | View → |
| May 6, 2026 | May 6 8:32 PM | CHRISTOPHER SULLIVAN | Proposed Sale | 47,000 | $16.26 | $764.2K | — | View → |
| May 6, 2026 | May 6 8:30 PM | PAUL VARKI | Proposed Sale | 92,771 | $16.26 | $1.5M | — | View → |
| May 6, 2026 | May 6 8:29 PM | MITCHELL CHAN | Proposed Sale | 3,167 | $16.26 | $51.5K | — | View → |
| Apr 30, 2026 | May 1 8:37 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 8,457 | $13.23 | $111.9K | 423(D) | View → |
| Apr 29, 2026 | May 1 8:37 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 8,458 | $13.09 | $110.7K | 8,880(D) | View → |
| Apr 29, 2026 | Apr 29 8:33 PM | CHRISTOPHER SULLIVAN | Proposed Sale | 16,915 | $12.86 | $217.5K | — | View → |
| Apr 6, 2026 | Apr 8 8:51 PM | Mittie DoyleChief Medical Officer | Sale | 3,970 | $18.01 | $71.5K | 3,622(D) | View → |
| Apr 6, 2026 | Apr 6 8:34 PM | MITTIE DOYLE | Proposed Sale | 65,800 | $17.76 | $1.2M | — | View → |
| Apr 2, 2026 | Apr 3 7:14 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 7,980 | $17.15 | $136.8K | 17,338(D) | View → |
| Apr 1, 2026 | Apr 3 7:14 PM | Christopher Ryan SullivanChief Financial Officer | Sale | 7,979 | $16.77 | $133.8K | 25,318(D) | View → |
| Apr 1, 2026 | Apr 3 7:13 PM | Mittie DoyleChief Medical Officer | Sale | 679 | $16.00 | $10.9K | 3,622(D) | View → |
| Apr 1, 2026 | Apr 1 8:48 PM | CHRISTOPHER SULLIVAN | Proposed Sale | 15,959 | $14.93 | $238.3K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 28, 2026 | Mar 31 8:09 PM | Jonathan GoldmanDirector | Option Exercise | 3,166 | — | 3,167(D) | View → |
| Mar 16, 2026 | Mar 18 8:07 PM | Mittie DoyleChief Medical Officer | Option Exercise | 25,492 | $12.65 | 149,008(D) | View → |
| Feb 26, 2026 | Mar 2 9:24 PM | Paul VarkiChief Legal Officer | Grant/Award | 80,000 | $17.64 | 80,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:23 PM | Jennifer RileyChief Strategy Officer | Grant/Award | 95,000 | $17.64 | 95,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:23 PM | Mittie DoyleChief Medical Officer | Grant/Award | 105,000 | $17.64 | 105,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:22 PM | Taylor BoydChief Business Officer | Grant/Award | 95,000 | $17.64 | 95,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:22 PM | Christopher Ryan SullivanChief Financial Officer | Grant/Award | 105,000 | $17.64 | 105,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:20 PM | Garry Arthur NeilDirector, Chief Executive Officer | Grant/Award | 286,000 | $17.64 | 286,000(D) | View → |
← Previous
Page 3 of 3